Observational studyFrontiers in endocrinology2026
Natural history of hypophosphatasia in Chinese patients younger than 18 years: a single-center retrospective observational study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To summarize the clinical features, natural history, and ALPL variant spectrum of Chinese children with hypophosphatasia (HPP), and to evaluate diagnostic features across clinical subgroups. Methods: This single-center retrospective observational study included children diagnosed with hypophosphatasia at our hospital who had not received enzyme replacement therapy. Published Chinese pediatric hypophosphatasia cases were also reviewed and combined with the single-center cohort for descriptive analyses. Results: Ninety-two children were included in the pooled cohort, comprising 23 patients in the single-center cohort and 69 cases identified from the literature. Baseline features were broadly comparable between single-center cohort and the literature cohort (P > 0.05). In the pooled cohort, there were 34 severe HPP (including 6 perinatal hypophosphatasia and 28 infantile hypophosphatasia), 34 childhood HPP, and 24 odonto-HPP. Median ages at onset were 0.09, 1.13, and 1.45 years, and median diagnostic delays were 0.15, 3.00, and 1.44 years, respectively. Height and weight Z-scores were lowest in severe HPP and least affected in odonto-HPP (all P < 0.001). Severe HPP had lower alkaline phosphatase, phosphate, and parathyroid hormone levels and higher calcium levels than the other groups. Among 70 genetically tested patients, 85 ALPL variants were identified; compound heterozygosity (78.6%) and missense variants (72.9%) predominated. In our single-center cohort, 3/8 severe HPP patients died, 4/9 childhood HPP patients progressed, and all 6 odonto-HPP patients remained stable during follow-up. Conclusion: Chinese pediatric hypophosphatasia is clinically and genetically heterogeneous. Earlier onset was associated with more severe biochemical abnormalities, impaired growth, and poorer outcomes. Childhood hypophosphatasia was prone to diagnostic delay and did not show spontaneous resolution. Atraumatic early loss of primary teeth and persistently low age- and sex-adjusted alkaline phosphatase are key to early recognition. However, larger prospective studies are required to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.